Please assess the completion status of the following clinical trial:

Trial Title: Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age 18 - 70~* History of intractable localization related/partial onset seizures and generalized tonic/clonic or tonic seizures defined according to International League Against Epilepsy (ILAE) classification as:~* A history compatible with localization related partial epilepsy~* A history of generalized tonic clonic or tonic seizures with loss of consciousness~* Three or more simple partial, complex partial or tonic-clonic seizures per month~* An EEG and/or an MRI consistent with a localization related epilepsy~* Evidence of at least three seizures per month for at least two months prior to the study~* Exposure to at least one antiepileptic drug at adequate dose~Exclusion Criteria:~* Significant or progressive medical, cardiac, or other illness~* Allergy to fish products or fish oil~* History of a coagulation disorder~* History of non-epileptic seizures~* Consumption of Fish Oil at any time 30 days or less prior to enrollment~* Any change in antiepileptic drugs for 30 days or less prior to enrollment~* Treatment with Warfarin for 30 days or less prior to enrollment~* Previous poor compliance with therapy~* Drug or alcohol abuse~* Uncountable seizures as a result of seizure clustering, or inadequate supervision if the patient cannot count their own seizures.~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Corn Oil Placebo (n-6 fatty acids)
- High Dose Fish Oil (Type: EXPERIMENTAL): 2160 mg of EPA + DHA
- Low Dose Fish Oil (Type: EXPERIMENTAL): 1060 mg of EPA + DHA

Based on this trial design, predict the completion outcome and termination type (if applicable).